Jocelyne Flament

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles et al. · Blood · 2020 · 378 citations · Full text

Medicine, Hematology, Oncology +12

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

Karin Janetzko, Jean‐Pierre Cazenave, Harald Klüter et al. · Transfusion · 2005 · 118 citations

Medicine, Hematology, Cell Therapy +16

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Qian Shi, Norbert Schmitz, Fang‐Shu Ou et al. · Journal of Clinical Oncology · 2018 · 108 citations · Full text

Medicine, Oncology, Cancer Control +9

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Matthew J. Maurer, Thomas M. Habermann, Norbert Schmitz et al. · Annals of Oncology · 2018 · 107 citations · Full text

Medicine, Oncology, Chemotherapy +13

ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Thomas E. Witzig et al. · Future Oncology · 2016 · 102 citations · Full text

Medicine, Hematology, Oncology +16